[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2193240T3 - Metodo y composicion para reconformar antigenos multi-epitopicos para iniciar una respuesta inmune. - Google Patents

Metodo y composicion para reconformar antigenos multi-epitopicos para iniciar una respuesta inmune.

Info

Publication number
ES2193240T3
ES2193240T3 ES96913660T ES96913660T ES2193240T3 ES 2193240 T3 ES2193240 T3 ES 2193240T3 ES 96913660 T ES96913660 T ES 96913660T ES 96913660 T ES96913660 T ES 96913660T ES 2193240 T3 ES2193240 T3 ES 2193240T3
Authority
ES
Spain
Prior art keywords
immune response
epithopic
reconform
antigens
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96913660T
Other languages
English (en)
Inventor
Ragupathy Madiyalakan
Antoine A Noujaim
Richard P Baum
Birgit Schultes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALTAREX CORP
ALTAREX Inc
Original Assignee
ALTAREX CORP
ALTAREX Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ALTAREX CORP, ALTAREX Inc filed Critical ALTAREX CORP
Application granted granted Critical
Publication of ES2193240T3 publication Critical patent/ES2193240T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A PROCEDIMIENTOS Y COMPOSICIONES PARA INICIAR Y/O MEJORAR UNA RESPUESTA INMUNE MEDIANTE LA PUESTA EN CONTACTO DE UN REACTIVO DE FIJACION CON UN ANTIGENO SOLUBLE, EN DONDE EL PAR REACTIVO DE FIJACION-ANTIGENO GENERA UNA RESPUESTA INMUNE PARA EL ANTIGENO.
ES96913660T 1996-05-15 1996-05-15 Metodo y composicion para reconformar antigenos multi-epitopicos para iniciar una respuesta inmune. Expired - Lifetime ES2193240T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB1996/000461 WO1997042973A1 (en) 1996-05-15 1996-05-15 Method and composition for reconforming multi-epitopic antigens to initiate an immune response

Publications (1)

Publication Number Publication Date
ES2193240T3 true ES2193240T3 (es) 2003-11-01

Family

ID=46171074

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96913660T Expired - Lifetime ES2193240T3 (es) 1996-05-15 1996-05-15 Metodo y composicion para reconformar antigenos multi-epitopicos para iniciar una respuesta inmune.

Country Status (17)

Country Link
US (7) US6241985B1 (es)
EP (2) EP1297846A1 (es)
JP (1) JP3565351B2 (es)
KR (1) KR20020011137A (es)
AT (1) ATE233102T1 (es)
BR (1) BR9612619A (es)
CA (1) CA2253602A1 (es)
DE (1) DE69626423T2 (es)
DK (1) DK0910407T3 (es)
ES (1) ES2193240T3 (es)
HU (1) HUP9903770A3 (es)
IL (1) IL126803A (es)
NO (2) NO321511B1 (es)
NZ (3) NZ505174A (es)
PT (1) PT910407E (es)
SI (1) SI0910407T1 (es)
WO (1) WO1997042973A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK85193D0 (da) 1993-07-16 1993-07-16 Cancerforskningsfondet Af 1989 Suppression of inhibitors
US20080220012A1 (en) * 1996-05-15 2008-09-11 Ragupathy Madiyalakan Therapeutic Compositions that alter the immune response
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
WO1997042973A1 (en) * 1996-05-15 1997-11-20 Altarex, Corp. Method and composition for reconforming multi-epitopic antigens to initiate an immune response
US20060159688A1 (en) * 1996-05-15 2006-07-20 Ragupathy Madiyalakan Method for diagnosing efficacy of xenotypic antibody therapy
US7318921B2 (en) * 1996-05-15 2008-01-15 Altarex Medical Corp. Therapeutic compositions that alter the immune response
JP2002518342A (ja) * 1998-06-15 2002-06-25 アルタレックス コーポレイション 抗原を変化させることにより免疫応答を産生する治療組成物
US6716966B1 (en) 1999-08-18 2004-04-06 Altarex Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
WO2001012217A1 (en) * 1999-08-18 2001-02-22 Altarex Corp. Therapeutic antibody against muc-1 antigen and methods for their use
US20050031619A1 (en) * 2001-03-21 2005-02-10 Nicodemus Christopher F. Therapeutic compositions that alter the immune response
GB2413960A (en) * 2001-03-21 2005-11-16 Altarex Inc Treating ovarian cancer
IL158316A0 (en) * 2001-04-10 2004-05-12 Univ Leland Stanford Junior Therapeutic and diagnostic uses of antibody specificity profiles
ES2304264A1 (es) * 2001-10-26 2008-10-01 Altarex Medical Corp. Terapia de combinacion para tratar enfermedades.
CA2481796A1 (en) * 2002-04-11 2003-10-23 Altarex Medical Corporation Binding agents and their use in targeting tumor cells
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
NZ563328A (en) 2002-10-16 2009-08-28 Euro Celtique Sa Antibodies that bind cell-associated CA 125/0772P and methods of use thereof
WO2004035003A2 (en) * 2002-10-17 2004-04-29 Altarex Medical Corporation Therapeutic adjuvant
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
WO2006099175A2 (en) * 2005-03-11 2006-09-21 Euro-Celtique S.A. Compositions comprising an anti-ca125 antibody and a cytotoxic compound and their use for the treatment of cancer
CA2617009C (en) * 2005-07-29 2017-02-28 Providence Health System Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response
EP1948802A4 (en) * 2005-10-13 2009-01-14 Virexx Medical Corp CHIMERIC ANTIGEN WITH HEPATITIS C VIRUS POLYPEPTIDE AND FC FRAGMENT FOR CALLING UP AN IMMUNE RESPONSE
JP2007320969A (ja) * 2007-09-10 2007-12-13 Altarex Medical Corp 免疫応答を惹起するための、多数エピトープ含有抗原の再構成法および組成物

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865689A (en) * 1972-11-09 1975-02-11 Hoffmann La Roche Method of producing carcinoembryonic antigens
US4348376A (en) * 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4939240A (en) * 1983-03-04 1990-07-03 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
US5053224A (en) 1983-11-07 1991-10-01 Hilary Koprowski Induction of antibody response to solid tumors with anti-idiotype antibodies
US4997762A (en) 1984-01-31 1991-03-05 Akzo N.V. Tumor associated monocoloal antibodies derived from human B-cell line
US4740371A (en) * 1984-09-17 1988-04-26 International Institute Of Cellular And Molecular Pathology Treatment of allergy
US4940670A (en) 1986-01-24 1990-07-10 Rhodes Buck A Method for compounding and testing patient specific monoclonal antibodies and monoclonal antibody fragments for in vivo use
GB8610983D0 (en) 1986-05-06 1986-06-11 Connaught Lab Enhancement of antigen immunogenicity
US5194254A (en) 1986-05-06 1993-03-16 Connaught Laboratories Limited Enhancement of antigen immunogenicity
US5084396A (en) * 1986-06-20 1992-01-28 Neorx Corporation Enhanced production of antibodies utilizing insolubilized immune complexes
US4879225A (en) * 1986-06-20 1989-11-07 Neorx Corporation Enhanced production of antibodies utilizing insolubilized immune complexes
US5009888A (en) 1987-04-13 1991-04-23 Genzyme Corporation Therapeutic enzyme-antibody complexes
US4921790A (en) * 1987-04-24 1990-05-01 Research Corporation Tumor specific assay for CA125 ovarian cancer antigen
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
EP0377657A1 (en) 1987-08-19 1990-07-18 Centocor, Inc. Human ovarian tumor-associated antigen specific for monoclonal antibody ov-tl3
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5140091A (en) * 1988-03-03 1992-08-18 Daicel Chemical Industries Ltd. Compositions of polyether compounds, epoxy compounds and processes for production thereof based on 4-vinylcyclohexene-1-oxide
US5183657A (en) 1988-03-11 1993-02-02 Celltech Limited Antibodies for use in antilymphocyte antibody therapy
CA1337403C (en) 1988-03-28 1995-10-24 Biomembrane Institute (The) Methods for the production of antibodies and induction of immune responses to tumor-associated gangliosides by immunization with ganglioside lactones
US5688657A (en) * 1988-03-31 1997-11-18 International Bio-Immune Systems, Inc. Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor
US5128119A (en) 1989-06-12 1992-07-07 Immunomedics, Inc. Methods for technetium/rhenium labeling of f(ab1)2 fragments
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5240833A (en) * 1989-01-30 1993-08-31 The Biomembrane Institute Method for the production of monoclonal antibodies directed to tumor-associated gangliosides and fucogangliosides
US5013547A (en) 1989-02-07 1991-05-07 Erbamont, Inc. Anticancer drug - antibody conjugates and method for preparing same
CA2047244C (en) * 1989-02-24 2002-09-17 Zanetti Maurizio Genetically engineered immunoglobulins
US6088613A (en) * 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5165922A (en) * 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
US5512283A (en) * 1990-07-06 1996-04-30 Allergene, Inc. Methods for the selective suppression of an immune response to dust mite der Pi
US6248332B1 (en) * 1990-10-05 2001-06-19 Medarex, Inc. Targeted immunostimulation with bispecific reagents
GB9108652D0 (en) * 1991-04-23 1991-06-12 Antisoma Ltd Immunoreactive compounds
US5976818A (en) * 1991-12-16 1999-11-02 The Board Of Trustees Of The University Of Arkansas Monoclonal antibodies which identify the glycoprotein carrying the CA 125 epitope
DE69231586T2 (de) 1992-01-03 2001-07-19 Rhomed, Inc. Pharmazeutische anwendungen auf der basis von peptid-metall-ionen
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
US6077519A (en) * 1993-01-29 2000-06-20 University Of Pittsburgh Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
JPH08510246A (ja) 1993-05-07 1996-10-29 アクゾ・ノベル・エヌ・ベー Ｈｉｖ免疫原性複合体
DE69422809T2 (de) * 1993-05-27 2000-10-12 Harald Schlebusch Monoklonale anti-idiotypische anti - CA125 Antikörper und sie enthaltende pharmazeutische Zusammensetzung
US5478556A (en) 1994-02-28 1995-12-26 Elliott; Robert L. Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor
US5532159A (en) * 1994-04-01 1996-07-02 The Ohio State University Monoclonal antibody to canine placental oncofetal protein for detecting cancer
AU704829B2 (en) * 1994-12-28 1999-05-06 University Of Kentucky Murine anti-idiotype antibody 3H1
US5807978A (en) * 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
DE19531226C1 (de) * 1995-08-24 1997-04-03 Immuno Ag Pharmazeutische Zusammensetzungen, enthaltend ein neutralisiertes Virus, und Verwendung derselben
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US7318921B2 (en) * 1996-05-15 2008-01-15 Altarex Medical Corp. Therapeutic compositions that alter the immune response
WO1997042973A1 (en) * 1996-05-15 1997-11-20 Altarex, Corp. Method and composition for reconforming multi-epitopic antigens to initiate an immune response
JPH1092532A (ja) * 1996-09-17 1998-04-10 Fujitsu Takamizawa Component Kk コネクタとｉｃカードコネクタ
US6140091A (en) * 1997-06-20 2000-10-31 Boston Biomedical Research Institute Anti-idiotype vaccines to elicit catalytic antibodies
US6052319A (en) * 1997-12-04 2000-04-18 Cypress Semiconductor Corp. Apparatus and method for controlling experimental inventory
KR100271642B1 (ko) * 1998-01-17 2000-11-15 김영환 다수의 문턱전압을 가지는 메모리 셀을 센싱 하는 회로 및 방법
JP3670839B2 (ja) * 1998-05-18 2005-07-13 オリンパス株式会社 共焦点顕微鏡

Also Published As

Publication number Publication date
IL126803A0 (en) 1999-08-17
NO20061203L (no) 1998-11-13
NO321511B1 (no) 2006-05-15
DE69626423D1 (de) 2003-04-03
KR20020011137A (ko) 2002-02-07
PT910407E (pt) 2003-07-31
NZ332588A (en) 2000-11-24
AU711270B2 (en) 1999-10-07
EP0910407B1 (en) 2003-02-26
IL126803A (en) 2003-11-23
SI0910407T1 (en) 2003-10-31
WO1997042973A1 (en) 1997-11-20
AU5658096A (en) 1997-12-05
US20080131443A1 (en) 2008-06-05
ATE233102T1 (de) 2003-03-15
US20080206318A1 (en) 2008-08-28
HUP9903770A3 (en) 2001-07-30
NZ516264A (en) 2002-04-26
BR9612619A (pt) 1999-07-20
NO985304L (no) 1998-11-13
EP0910407A1 (en) 1999-04-28
NO985304D0 (no) 1998-11-13
US6086873A (en) 2000-07-11
EP1297846A1 (en) 2003-04-02
US20010036457A1 (en) 2001-11-01
US20070036798A1 (en) 2007-02-15
JP3565351B2 (ja) 2004-09-15
JPH11509558A (ja) 1999-08-24
US20080311127A1 (en) 2008-12-18
NZ505174A (en) 2002-03-01
US6241985B1 (en) 2001-06-05
HUP9903770A2 (hu) 2000-03-28
CA2253602A1 (en) 1997-11-20
DK0910407T3 (da) 2003-06-16
DE69626423T2 (de) 2004-03-18

Similar Documents

Publication Publication Date Title
ES2193240T3 (es) Metodo y composicion para reconformar antigenos multi-epitopicos para iniciar una respuesta inmune.
DK1223973T3 (da) Fremgangsmåde til at udtrykke antigener på overfladen af antigenpræsenterede celler ved fotokemisk internalisation
ATE329617T1 (de) Antigen enthaltende zusammensetzung, die zusätzlich derivatisierte monoglyceride oder diglyceride als adjuvantien enthält
EA199700272A1 (ru) Вакцины, содержащие сапонин и стерин
GEP20105118B (en) Anti-vegf antibodies
CY1108307T1 (el) Αντιγονα και εμβολια εντεροκοκκου
AU3438900A (en) Use of trehalose for stabilising a liquid vaccine
CR20120505A (es) Composición de fármaco conjugado
ATE264911T1 (de) Eine universelle immunmodulatorische cytokin- expressierende zelllinie in wartestelling. entsprechende zusammensetzungen und methoden ihrer herstellung und verwendungen
WO2003039470A3 (en) Polyvalent immunogen of hiv
TR200000740T2 (tr) Dişleri beyazlatmak için metod ve kompozisyonlar.
EP2258712A3 (en) Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
AR055422A2 (es) Composicion de antigeno, composicion de vacuna y procedimiento para tratar un cerdo
ES2100874T3 (es) Soporte para muestras de perfume.
MY104946A (en) Antigen antibody conjugate.
EA199900069A1 (ru) Вакцинная композиция против малярии
ES2171851T3 (es) Procedimiento y maquina de soldadura o estañado a la ola.
AR009636A1 (es) Un metodo para la determinacion de un anticuerpo de la clase de inmunoglobulina g especifico contra antigenos.
ES2177927T3 (es) Composicion para provocar una reaccion inmunologica a un determinante antigenico no proteinico.
IL139601A0 (en) Compositions and methods of modulating an immune response to an antigen
NZ333265A (en) Vaccine containing peroxiredoxin and/or beta-tubulin of fluke origin to immunise against parasitic infestation of helminths in mammals
AP2001002073A0 (en) Neutralizing antibody and immunomodulatory enhancing compositions
EP0153871A3 (en) Antibody enhancement of immunogenicity of antigen
AU6176596A (en) Compositions exhibiting adp-ribosyltransferase activity and methods for the preparation and use thereof
AU4537100A (en) Adjuvant combinations for immunization composition and vaccines